Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
https://endpts.com/adding-billions-in-value-eli-lilly-succeeds-where-pfizer-failed-halting-breast-cancer-recurrence/
Ibrance (Palbociclib) is getting outclassed. Maybe time to add a synergistic BETi to it?